Xeris Lifts 2026 Revenue Guidance to $395M–$405M After 44% Q3 Growth
XERS has more than doubled off its 52-week low of $5.25.
Summary
Xeris raised full-year 2026 revenue guidance to $395M–$405M, though the release does not disclose the prior range, and lifted its 2030 revenue view to more than $1B. Q3 revenue jumped 44% year over year to $107.2M, driven by patient demand for Recorlev, and net income came in at $11.3M versus $0.6M a year earlier. Adjusted EBITDA rose $13.3M year over year to $30.8M, and gross margin expanded to 88% from 85%. The quarter follows a Q2 that showed 29% revenue growth but a $31.1M net loss from a non-cash debt extinguishment charge, so the swing to profit marks a clean step up. Next checkpoint is initiation of the XP-8121 Phase 3 study, targeted by year-end 2026.
At the time of this announcement, XERS was trading at $10.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.25 to $11.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.